Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.70% | -50.96% | 54.88% | -54.99% | -79.04% |
| Total Depreciation and Amortization | 3.42% | 43.87% | -34.41% | -20.42% | -19.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.52% | 136.49% | 90.88% | 22.43% | -1.66% |
| Change in Net Operating Assets | -54.38% | 17,584.57% | -2,132.61% | 42.57% | -179.45% |
| Cash from Operations | -29.14% | 67.61% | -24.97% | -63.65% | -104.88% |
| Capital Expenditure | 73.26% | -110.53% | 56.66% | 59.62% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.83% | -440.09% | 249.58% | 22.04% | 170.01% |
| Cash from Investing | -22.79% | -439.49% | 248.91% | 22.17% | 169.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -32.51% | 838.64% | -95.29% | 263.81% | -94.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 2,489.01% | 98.62% | 100.00% | 98.01% |
| Cash from Financing | -30.99% | 1,042.63% | -95.57% | 607.41% | -94.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -316.81% | 142.43% | -43.53% | -93.08% | 248.59% |